Metabolic/Obesity Approved Deal Benchmarks (2026)
Median upfront of $3.5B with total deal values reaching $10.3B.
Median Upfront
$3.5B
Total Deal Value
$9.0B
Royalty Range
23.2%–30%
Territory Multiplier
1x
Understanding Metabolic/Obesity Deal Benchmarks at Approved
Approved Metabolic/Obesity licensing deals command a median upfront payment of $3.5B, with values ranging from $2.6B at the low end to $4.1B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $7.6B to $10.3B, with a median of $9.0B. Royalty rates for metabolic/obesity assets at this stage typically fall between 23.2% and 30% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $2.6B | $3.5B | $4.1B |
| Total Deal Value | $7.6B | $9.0B | $10.3B |
| Royalty Rate | 23.2% | — | 30% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2021 | Dicerna Pharmaceuticals | Novo Nordisk | $3.3B | $3.3B | acquisition |
| 2024 | Scribe Therapeutics | Novo Nordisk | $55M | $1.6B | licensing |
| 2024 | MBX Biosciences | Novo Nordisk | $40M | $610M | licensing |
| 2024 | Amgen | N/A (internal) | $0M | $1.9B | collaboration |
| 2024 | Boehringer Ingelheim | Zealand Pharma | $100M | $1.8B | licensing |
| 2023 | Structure Therapeutics | Roche | $150M | $3.7B | licensing |
| 2024 | Catalent | Novo Holdings | $16.5B | $16.5B | acquisition |
| 2022 | Pliant Therapeutics | Novartis | $60M | $490M | collaboration |
| 2021 | Xeris Pharmaceuticals | Tetris Pharma | $0M | $71M | reformulation |
See All Comparable Deals
View 9 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Metabolic/Obesity deals?
How does Global territory affect Metabolic/Obesity deal value?
What royalty rates are typical for Approved Metabolic/Obesity licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$77M upfront
Metabolic/Obesity · Preclinical · Global
$229M upfront
Metabolic/Obesity · Phase 1 · Global
$589M upfront
Metabolic/Obesity · Phase 2 · Global
$1.2B upfront
Metabolic/Obesity · Phase 3 · Global
$2.1B upfront
Oncology · Approved · Global
$1.5B upfront
Neurology/CNS · Approved · Global
$3.4B upfront
Immunology · Approved · Global
$1.9B upfront
Metabolic/Obesity · Approved · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Metabolic/Obesity Approved Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/metabolic-approved-deals-global
<a href="https://solidus.ambrosiaventures.co/data/metabolic-approved-deals-global">Metabolic/Obesity Approved Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=metabolic&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.